Organoids are reshaping cancer R&D by providing more accurate, patient-relevant models than classical methods. By bridging the gap between preclinical and early clinical stages, they enable patient-centric target validation, drug discovery, and therapeutic development, representing a significant step toward truly precision oncology
SLAS announces finalists for the 2026 Ignite Award
Associations, Latest NewsThe Society for Laboratory Automation and Screening (SLAS) has unveiled the Ignite Award finalists: eight pioneering lab automation and drug discovery start-ups competing for $5,000 at SLAS 2026 in Boston, 7-11 February 2026.
German pure-play biosimilar developer Formycon agrees licensing and supply deal for U.S. and Canada
Latest NewsFormycon AG and Zydus Lifesciences Limited today jointly announced a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (Pembrolizumab), in the U.S. and Canada, the companies said in a statement.
Tiny Models, Big Impact
slider, Sponsored PublicationsOrganoids are reshaping cancer R&D by providing more accurate, patient-relevant models than classical methods. By bridging the gap between preclinical and early clinical stages, they enable patient-centric target validation, drug discovery, and therapeutic development, representing a significant step toward truly precision oncology
Melt&Marble secures €7.3m Series A to scale designer fats
Latest NewsSwedish Melt&Marble AB has raised €7.3m to scale precision-fermented designer fats for sustainable, high-performance food and personal care ingredients.
Poolbeg takes centre stage in CRS research
Latest NewsCancer immunotherapies can save lives, yet their side effect — cytokine release syndrome (CRS) — remains a barrier for wider use, even though IL 6 receptor antagonists can treat it. Now the UK company Poolbeg Pharma plc, together with Johnson & Johnson, investigates how CRS might be prevented. The programme is backed by a £3.4m grant from the MRC.
Orano Med and Roche advance towards clinical programme in radiopharmacy
Latest NewsOrano Med and Roche have launched a clinical development programme for CEA‑targeted two‑step PRIT using lead‑212, with Orano supplying the ²¹²Pb, while Novartis and ITM are expanding production of alpha‑emitting radiopharmaceuticals.
EU trilogue sets clear path for new genomic techniques
Latest NewsAfter four EU Council presidencies, EU member states and the European Parliament yesterday struck a provisional deal on new genomic techniques under the current Danish presidency, setting clear rules to boost agrifood innovation, plant resilience, transparency and sustainability.
Topical DHT blockade demonstrates significant efficacy
Latest NewsClascoterone 5% topical solution has demonstrated significant hair growth in Phase III trials, showing strong efficacy and a favourable safety profile in men with androgenetic alopecia.
UK hikes drug prices after pharma exodus
Latest NewsAfter the withdrawal of investment pledges totalling £2bn by pharmaceutical companies — seeking to offset lower US revenue by raising UK prices — the British government has now caved in and signed a deal with the US administration that will lift UK drug prices by 25%
Angelini Ventures and EIB launch joint start-up financing
Latest NewsThe European Investment Bank (EIB) and Angelini Ventures, the corporate venture capital arm of Angelini Industries, have signed an agreement to jointly provide €150m over the next six years to support European biotechnology and digital health start-ups through seven to ten funding rounds. This marks the EIB’s first partnership with a corporate venture capital firm in Europe’s health sector under its TechEU programme.